IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 201-225 out of 1365.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

Public Release: 3-Jun-2016
Molecular Cancer Therapeutics
Testing blood metabolites could help tailor cancer treatment
Testing for metabolic changes in the blood could indicate whether a cancer drug is working as designed, a new study reports.
Wellcome Trust, Cancer Research UK, Roche

Contact: Sophia McCully
Institute of Cancer Research

Public Release: 3-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
CTCA Western clinical research director authors five innovative studies presented at ASCO
Advances in lung cancer, ovarian cancer and new immunotherapy treatments are among the scientific studies presented this year at ASCO by Dr. Glen Weiss, Director of Clinical Research at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western). Dr. Weiss has overseen a substantial number of innovative clinical trials since he began supervising clinical research at CTCA Western in 2013.

Contact: Steve Yozwiak
Cancer Treatment Centers of America

Public Release: 3-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
St. Jude Children's Research Hospital research being presented at ASCO Annual Meeting
St. Jude Children's Research Hospital research related to survivorship and the pediatric solid tumors neuroblastoma, adrenocortical carcinoma and nasopharyngeal carcinoma will be presented at the 2016 American Society of Clinical Oncology Annual Meeting. The five-day event begins June 3 in Chicago.

Contact: Jann Ingmire
St. Jude Children's Research Hospital

Public Release: 3-Jun-2016
American Society of Clinical Oncology Annual Meeting
Chemotherapy and exercise: The right dose of workout helps side effects
Researchers at the University of Rochester Wilmot Cancer Institute discovered something simple and inexpensive to reduce neuropathy in hands and feet due to chemotherapy -- exercise.
NIH/National Cancer Institute

Contact: Leslie Orr
University of Rochester Medical Center

Public Release: 3-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Investigational immunotherapy drug shrinks tumors in high-risk neuroblastoma patients
St. Jude Children's Research Hospital investigators report promising preliminary results at the annual meeting of ASCO for an experimental monoclonal antibody when combined with chemotherapy for newly diagnosed patients.
Cookies for Kids' Cancer, ALSAC

Contact: Jann Ingmire
St. Jude Children's Research Hospital

Public Release: 3-Jun-2016
Nature Communications
Promising treatment prospects for invasive breast cancer
Scientists from the University of Zurich have been able to understand for the first time why many cancer cells adapt relatively quickly to the treatment with therapeutic antibodies in invasive forms of breast cancer. Instead of dying off, they are merely rendered inactive. The researchers have now developed an active substance that kills the cancer cells very effectively without harming healthy cells.
Swiss Cancer League, Swiss Cancer Research foundation, Swiss National Science Foundation, EU FP7 program AFFINOMICS, University of Zurich

Contact: Andreas Plueckthun
University of Zurich

Public Release: 3-Jun-2016
Cancer cell immunity in the crosshairs: Worth the expense?
Japanese scientists have found unique genetic alterations that could indicate whether expensive immune checkpoint inhibitors would be effective for a particular patient. Publishing in Nature, the study reports that genetic alterations affecting a part of the PD-L1 gene increases the production of the protein, allowing cancer cells to escape detection by the immune system.
Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, National Cancer Center

Contact: Anna Ikarashi
Kyoto University

Public Release: 3-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Cancer patients miss appointments, prescriptions due to inability to afford care
A study led by University of North Carolina Lineberger Comprehensive Cancer Center researchers found that more than one-in-four cancer patients had to pay more for medical care than they could afford, and 18 percent of those patients said they were unable to afford prescription medications.

Contact: Bill Schaller
University of North Carolina at Chapel Hill

Public Release: 3-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Researchers report improved progression-free survival for lutathera over octreotide
Moffitt Cancer Center will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, 2016 during the American Society of Clinical Oncology Annual Meeting in Chicago.

Contact: Steve Blanchard
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 3-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Counseling patients at risk for cancer over the phone reduces costs and access burdens
Delivering genetic test results to patients at risk for cancer-causing genetic mutations over the phone helps to ease cost and transportation burdens and, compared to receiving results in person, does not cause patients additional stress, according to a new study from the Abramson Cancer Center of the University of Pennsylvania which will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (abstract 1502).
NIH/National Cancer Institute

Contact: Stephen Graff
University of Pennsylvania School of Medicine

Public Release: 3-Jun-2016
Proceedings of the National Academy of Sciences
Mechanisms of persistent infection for the human T-cell leukemia virus
Joint research between scientists from Kumamoto University, Japan and Imperial College London, UK has revealed the mechanisms of persistent latent infection of the human T-cell leukemia virus type 1 (HTLV-1). This is an important achievement that may contribute to the prevention of refractory leukemia, a form of leukemia in which leukemic cells do not respond well to treatment.
Grant-in-Aid for Scientific Research, Program to Disseminate Tenure Track System, Japan Agency for Medical Research and Development, CREST

Contact: J. Sanderson, N. Fukuda
Kumamoto University

Public Release: 2-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
International trial changing standard of care for advanced breast cancer
Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed.
Turkish Federation of Societies for Breast Diseases

Contact: Allison Hydzik
University of Pittsburgh Schools of the Health Sciences

Public Release: 2-Jun-2016
Cancer Research
Cancer cells become more aggressive from fat storage
It has been established that not all cancer cells are equally aggressive -- most can be neutralised with radiation and chemotherapy. Researchers at Lund University in Sweden have now discovered that some cancer cells can accumulate fat droplets, which appear to make them more aggressive and increase their ability to spread

Contact: Cecilia Schubert
Lund University

Public Release: 2-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Lancet Oncology
Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows
A new Moffitt Cancer Center study being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published in The Lancet Oncology shows that utilizing the immunotherapeutic agents nivolumab and ipilimumab could lead to more effective treatment options for SCLC patients who fail initial therapy.

Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 2-Jun-2016
JAMA Oncology
Frailty among young bone marrow transplant survivors increases risk of death
The prevalence of frailty in young bone marrow transplant survivors is similar to that seen in the elderly population and frailty is associated with an increased risk of subsequent death, according to a new study published online by JAMA Oncology.

Contact: Beena Thannickal
The JAMA Network Journals

Public Release: 2-Jun-2016
Journal of Investigative Dermatology
Topical skin creams effective to treat superficial basal cell carcinoma: New study
Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services. Topical treatments are available for superficial basal cell carcinoma (BCC) but there has a lack of long-term follow-up data to guide treatment decisions. A three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT).

Contact: George Woodward

Public Release: 2-Jun-2016
Nature Communications
CNIO scientists have created mice with hyper-long telomeres without altering the genes
The Telomeres and Telomerase Group at the CNIO has succeeded in creating mice in the laboratory with hyper-long telomeres and with reduced molecular ageing, avoiding the use of genetic manipulation. This new technique based on epigenetic changes avoids the manipulation of genes in order to delay molecular ageing. The study also underlines the importance of this new strategy in generating embryonic stem cells and iPS cells with long telomeres for use in regenerative medicine.
Spanish Ministry of Economy and Competitiveness, European Research Council, Regional Government of Madrid, AXA Research Fundation, Botín Foundation and Banco Santander through Santander Universities

Contact: Nuria Noriega
Centro Nacional de Investigaciones Oncológicas (CNIO)

Public Release: 2-Jun-2016
Cell Chemical Biology
Novel compound shows promise against breast cancer
A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.
National Institutes of Health, Pelotonia

Contact: Jesse Kwiek
Ohio State University

Public Release: 2-Jun-2016
Cancer Cell
New mouse models give a boost to the development of cancer immunotherapies
A new cancer treatment called CD40 inhibitor has yielded disappointing results when tested in clinical trials, failing to mobilize patients' immune system against tumors the way it was expected to. But a recent study offers clues about how this experimental drug might be optimized to fulfill its potential.
National Institutes of Health, Robertson Therapeutic Development Fund

Contact: Eva Kiesler
Rockefeller University

Public Release: 2-Jun-2016
Researchers uncover how 'silent'genetic changes drive cancer
Small molecules called tRNA, whose job is to help translate genes into proteins, are not usually considered important for understanding the causes of disease. But a new study shows that fluctuations in some tRNAs may in fact influence the progression of breast cancer.
National Institutes of Health, Department of Defense

Contact: Eva Kiesler
Rockefeller University

Public Release: 2-Jun-2016
Cancer Prevention Research
Walnuts may improve your colon health
Eating walnuts may change gut bacteria in a way that suppresses colon cancer, researchers led by UConn Health report in the journal Cancer Prevention Research. A team of researchers found that mice that ate 7-10.5 percent of their total calories as walnuts developed fewer colon cancers. The effect was most pronounced in male mice, which had 2.3 times fewer tumors when fed walnuts as part of a diet similar to the typical American's.
California Walnut Commission, American Institute for Cancer Research

Contact: Kim Krieger
University of Connecticut

Public Release: 2-Jun-2016
Nature Cell Biology
Mayo Clinic uncovers how 1 gene, protein suppresses tumor formation
Pten (short for phosphatase and tensin homolog) is a tumor suppressor that is defective in about 20-25 percent of all patients with cancers. Mayo Clinic researchers now have discovered that Pten safeguards against tumor formation by keeping chromosome numbers intact when a cell splits into two daughter cells.
National Institutes of Health

Contact: Bob Nellis
Mayo Clinic

Public Release: 2-Jun-2016
Journal of Leukocyte Biology
Finely tuned electrical fields give wound healing a jolt
A new research report appearing in the June 2016 issue of the Journal of Leukocyte Biology, opens up the possibility that small electrical currents might activate certain immune cells to jumpstart or speed wound healing. This discovery, made by a team of scientists from the United Kingdom, may be of particular interest to those with illnesses that may cause wounds to heal slowly or not at all.
Kidney Research UK, Institute of Medical Sciences University

Contact: Cody Mooneyhan
Federation of American Societies for Experimental Biology

Public Release: 2-Jun-2016
Nucleic Acids Research
New free web service for deep study of cell functions
Scientists from Russia, US, Canada and Germany have developed a simple and effective web service that enables a better understanding of cell functions by identifying links between changes in metabolism and gene expression. New insights gained by means of the service can be applied to develop treatments for autoimmune diseases and cancer, since metabolic regulation plays a major role in such biological processes.
Government of Russian Federation, Washington University in St. Louis

Contact: Dmitry Malkov
ITMO University

Public Release: 2-Jun-2016
Journal of Biological Chemistry
Olfactory receptor discovered in pigment cells of the skin
Pioneering researchers provided proof of an odorant receptor in pigment-producing cells in the human skin, so-called melanocytes. The team demonstrated that the violet-like Beta-Ionone odorant activates the receptor. The researchers identified the signalling pathways in detail that trigger an activation of the receptor. They consider their results a starting point for the therapy of malign melanoma.
German Research Foundation, Vogelsang Foundation

Contact: Hanns Hatt
Ruhr-University Bochum

Showing releases 201-225 out of 1365.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

  Search News Releases